NCT05285904Completed
Kesimpta® (Ofatumumab) in Swiss Multiple Sclerosis Patients - an Observational Study
Kesimpta® (Ofatumumab) in Swiss Multiple Sclerosis Patients - an Observational Study (KOSMOS)
Source: ClinicalTrials.gov · Last updated 14 Apr 2026
Brief summary (registry, in English)
This is a multi-center, observational study carried out in Switzerland that aims to describe the effects of Ofatumumab in a setting of routine medical care.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 107 (actual)
- First submitted
- 8 Mar 2022
- Start date
- 12 May 2022
- Primary completion date
- 4 Feb 2026
- Lead sponsor
- Novartis Pharmaceuticals
- Diseases
- Multiple sclerosis
- NCT number
- NCT05285904
What you commit to
- Study type: Observational
- Participants enrolled: 107
- From 12 May 2022 to the primary completion date, 4 Feb 2026
- 9 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of investigational drugs during the study, OR between Ofatumumab initiation and inclusion into the study, OR within 3 months before Ofatumumab initiation, OR within 5 half-lives of investigational drug before Ofatumumab initiation, OR until the expected pharmacodynamic effect has returned to baseline, whichever is longer.
Other
- Subjects who are not able to provide consent due to incapable judgement
Who the study is looking for
- Written informed consent must be obtained before participating in the study.
- Diagnosis of RMS per McDonald Criteria (2017) occurred within 3 years prior to initiation of Ofatumumab.
- Adult patients who have been on treatment with Ofatumumab for at least 3 months, but not longer than 12 months prior to inclusion in the study.
- Ofatumumab treatment in line with the Swiss Kesimpta® label (i.e. adult patients with active, relapsing forms of MS)
- Patient is willing and able to complete patient diary during course of the study, as well as to complete PRO questionnaires.
Age in the registry: 18 years to 99 years · Sex: All · Does not accept healthy volunteers
Sites (9)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Baden | Switzerland | Unknown status |
| - Coordinator of this site? Confirm its status | Basel | Switzerland | Unknown status |
| - Coordinator of this site? Confirm its status | Bern | Switzerland | Unknown status |
| - Coordinator of this site? Confirm its status | Gland | Switzerland | Unknown status |
| - Coordinator of this site? Confirm its status | Lausanne | Switzerland | Unknown status |
| - Coordinator of this site? Confirm its status | Lucerne | Switzerland | Unknown status |
| - Coordinator of this site? Confirm its status | Lugano | Switzerland | Unknown status |
| - Coordinator of this site? Confirm its status | Sargans | Switzerland | Unknown status |
| - Coordinator of this site? Confirm its status | Zurich | Switzerland | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.